These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 9099379)

  • 1. Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection.
    Larson LJ; Schultz RD
    Am J Vet Res; 1997 Apr; 58(4):360-3. PubMed ID: 9099379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal vaccination of pups in the presence of maternally derived antibodies to canine parvovirus (CPV). Evaluation of minimal immunizing dose.
    Buonavoglia C; Cavalli A; Tempesta M; Voight V; Buonavoglia D; Corrente M; Sagazio P
    New Microbiol; 1995 Oct; 18(4):371-5. PubMed ID: 8590389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of two canine parvovirus vaccines for inducing seroconversion in Rottweiler and Doberman pinscher pups with various levels of maternally derived antibodies.
    Coyne MJ
    Vet Ther; 2000; 1(1):35-42. PubMed ID: 19757563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CPV-2b and CPV-2c.
    Siedek EM; Schmidt H; Sture GH; Raue R
    Berl Munch Tierarztl Wochenschr; 2011; 124(1-2):58-64. PubMed ID: 21306055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant?
    Larson LJ; Schultz RD
    Vet Ther; 2008; 9(2):94-101. PubMed ID: 18597247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody levels and protection to canine parvovirus type 2.
    Elia G; Cavalli A; Cirone F; Lorusso E; Camero M; Buonavoglia D; Tempesta M
    J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):320-2. PubMed ID: 16316392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of puppies to canine-origin parvovirus vaccines.
    Carmichael LE; Pollock RV; Joubert JC
    Mod Vet Pract; 1984 Feb; 65(2):99-102. PubMed ID: 6328258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus.
    Gore TC; Lakshmanan N; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
    Vet Ther; 2005; 6(1):5-14. PubMed ID: 15906266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternally-derived antibodies in pups and protection from canine parvovirus infection.
    Decaro N; Campolo M; Desario C; Elia G; Martella V; Lorusso E; Buonavoglia C
    Biologicals; 2005 Dec; 33(4):261-7. PubMed ID: 16168665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus.
    Spibey N; Greenwood NM; Sutton D; Chalmers WS; Tarpey I
    Vet Microbiol; 2008 Apr; 128(1-2):48-55. PubMed ID: 18006253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year rabies duration of immunity in dogs following vaccination with a core combination vaccine against canine distemper virus, canine adenovirus type-1, canine parvovirus, and rabies virus.
    Lakshmanan N; Gore TC; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
    Vet Ther; 2006; 7(3):223-31. PubMed ID: 17039445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c.
    Wilson S; Illambas J; Siedek E; Stirling C; Thomas A; Plevová E; Sture G; Salt J
    Vaccine; 2014 Sep; 32(42):5420-4. PubMed ID: 25148778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serologic response of pups to the low-passage, modified-live canine parvovirus-2 component in a combination vaccine.
    O'Brien SE
    J Am Vet Med Assoc; 1994 Apr; 204(8):1207-9. PubMed ID: 8014088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum distemper virus and parvovirus antibody titers among dogs brought to a veterinary hospital for revaccination.
    McCaw DL; Thompson M; Tate D; Bonderer A; Chen YJ
    J Am Vet Med Assoc; 1998 Jul; 213(1):72-5. PubMed ID: 9656027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early protection of puppies against canine parvovirus: a comparison of two vaccines.
    McCaw DL; Tate D; Dubovi EJ; Johnson JC
    J Am Anim Hosp Assoc; 1997; 33(3):244-50. PubMed ID: 9138235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain.
    Pratelli A; Altamura M; Buonavoglia D; Pepe M; Tafaro A; Lembo A; Cirone F; Tempesta M; Jirillo E; Buonavoglia C
    Immunopharmacol Immunotoxicol; 2000 Aug; 22(3):451-64. PubMed ID: 10946825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of pups with maternally derived antibodies to canine parvovirus (CPV) using a modified-live variant (CPV-2b).
    Pratelli A; Cavalli A; Normanno G; De Palma MG; Pastorelli G; Martella V; Buonavoglia C
    J Vet Med B Infect Dis Vet Public Health; 2000 May; 47(4):273-6. PubMed ID: 10861195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternally derived immunity to canine parvovirus infection: transfer, decline, and interference with vaccination.
    Pollock RV; Carmichael LE
    J Am Vet Med Assoc; 1982 Jan; 180(1):37-42. PubMed ID: 7056660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal vaccination of pups with maternally derived antibodies with a modified live canine parvovirus.
    Buonavoglia C; Cavalli A; Gravino E; Voigt V; Buonavoglia D; de Caprariis D
    Zentralbl Veterinarmed B; 1994 Mar; 41(1):3-8. PubMed ID: 7941844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of canine parvovirus--a need for new vaccines?
    Truyen U
    Vet Microbiol; 2006 Oct; 117(1):9-13. PubMed ID: 16765539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.